Molecular Templates, Inc.
9301 Amberglen Blvd, Ste 100
Austin
TX
78729
United States
Tel: 512-869-1555
Website: http://mtem.com/
Email: careers@mtem.com
About Molecular Templates, Inc.
Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from antibody drug conjugates (ADCs). MTEM is developing MT-6402, which is in a Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients; MT-5111, which is in a Phase I clinical trial for the treatment of HER2-positive cancers; and MT-0169, which is in a Phase I clinical trial to treat relapsed/refractory myeloma. Additional preclinical compounds derived from our ETB platform technology are being advanced toward clinical development. Additional information about MTEM can be obtained at www.mtem.com.
OWNERSHIP: Public
STOCK SYMBOL: MTEM
STOCK EXCHANGE: NASDAQ
96 articles about Molecular Templates, Inc.
-
Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results
11/10/2022
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results and business updates for the third quarter of 2022.
-
Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
11/4/2022
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today announced that it will present four abstracts and host an in-person Research & Development Day, Friday, November 11, 2022, at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting which will be held November 8 – 12, 2022 at the Boston Convention and Exhibition Center in Boston, MA.
-
Molecular Templates Announces Participation in Four Upcoming Conferences
8/31/2022
Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), will participate in the following September 2022 conferences.
-
Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results
8/11/2022
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), today reported financial results and business updates for the second quarter of 2022.
-
Molecular Templates’ Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs
6/6/2022
Molecular Templates, Inc. announces highlights from the two poster presentations on its clinical programs that were presented on June 5th at the 2022 American Society of Clinical Oncology annual meeting, taking place June 3 through June 7, 2022 at the McCormick Place Convention Center in Chicago, IL.
-
Molecular Templates to Present at Upcoming Investor Conferences - May 17, 2022
5/17/2022
Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, will participate in the following upcoming investor conferences.
-
Molecular Templates, Inc. Reports First Quarter 2022 Financial Results
5/12/2022
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2022.
-
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach
4/12/2022
Molecular Templates, Inc. reviews highlights from the six poster presentations on its pipeline programs that were presented at the American Association of Cancer Research (AACR) Annual Meeting 2022, taking place April 8 - April 13, 2022.
-
Molecular Templates to Host Webinar on a Unique Approach to Immuno-Oncology for Solid Tumors
4/8/2022
Molecular Templates, Inc. announced that it will host a webinar on a unique approach to immuno-oncology for solid tumors on Wednesday, April 13, 2022 at 8:00 am Eastern Time.
-
Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results
3/28/2022
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the fourth quarter of 2021.
-
Molecular Templates Strengthens Board of Directors and Management Team
3/2/2022
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the appointment of Gabriela Gruia, M.D., to its Board of Directors and the promotion of Megan Filoon to General Counsel.
-
Molecular Templates to Present at the Upcoming Investor Conferences - Mar 01, 2022
3/1/2022
Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies, which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, will participate in several upcoming investor conferences.
-
Molecular Templates Provides Corporate Update and Outlines 2022 Milestones
11/30/2021
Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, provided a corporate update and outlined expected 2022 milestones.
-
Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402
11/18/2021
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for MT-6402 for the treatment of patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1.
-
Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results
11/15/2021
Molecular Templates, Inc. today reported financial results for the third quarter of 2021.
-
Molecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
9/20/2021
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, will present and participate in 1-on-1 investor meetings at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.
-
Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results
8/12/2021
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2021.
-
Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors
7/9/2021
Molecular Templates, Inc. today announced the dosing of the first subject in a Phase 1 study investigating MT-6402 in patients with PD-L1-positive solid tumors.
-
Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference
7/6/2021
Molecular Templates, Inc. announced that it will provide a corporate update and participate in 1-on-1 investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to take place July 13-14, 2021.
-
Molecular Templates, Inc. Reports First Quarter 2021 Financial Results
5/13/2021
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2021.